CN104546870B - 一种避孕药 - Google Patents
一种避孕药 Download PDFInfo
- Publication number
- CN104546870B CN104546870B CN201510039588.6A CN201510039588A CN104546870B CN 104546870 B CN104546870 B CN 104546870B CN 201510039588 A CN201510039588 A CN 201510039588A CN 104546870 B CN104546870 B CN 104546870B
- Authority
- CN
- China
- Prior art keywords
- contraceptive
- mestranols
- ethinyloestradiols
- drospirenones
- cyproterones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002254 contraceptive effect Effects 0.000 title claims abstract description 32
- 239000003433 contraceptive agent Substances 0.000 title claims abstract description 28
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 25
- 229960004400 levonorgestrel Drugs 0.000 claims abstract description 23
- 229930006000 Sucrose Natural products 0.000 claims abstract description 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 19
- 239000005720 sucrose Substances 0.000 claims abstract description 19
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims abstract description 17
- 229960002568 ethinylestradiol Drugs 0.000 claims abstract description 16
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960004845 drospirenone Drugs 0.000 claims abstract description 13
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims abstract description 13
- 229960003843 cyproterone Drugs 0.000 claims abstract description 11
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims abstract description 11
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims abstract description 7
- 229960001390 mestranol Drugs 0.000 claims abstract description 7
- 239000001913 cellulose Substances 0.000 claims description 17
- 229920002678 cellulose Polymers 0.000 claims description 17
- 235000010980 cellulose Nutrition 0.000 claims description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 12
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical class C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 229960004913 dydrogesterone Drugs 0.000 claims description 6
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 5
- 229960005352 gestodene Drugs 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000186 progesterone Substances 0.000 claims description 4
- 229960003387 progesterone Drugs 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- -1 hydroxymethyl-propyl Chemical group 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 claims description 2
- 229950011191 norgesterone Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 240000000111 Saccharum officinarum Species 0.000 claims 3
- 235000007201 Saccharum officinarum Nutrition 0.000 claims 3
- 239000003292 glue Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 abstract description 11
- 239000000262 estrogen Substances 0.000 abstract description 11
- 229940088597 hormone Drugs 0.000 abstract description 6
- 239000005556 hormone Substances 0.000 abstract description 6
- 230000001072 progestational effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 13
- 230000016087 ovulation Effects 0.000 description 6
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 5
- 229940127234 oral contraceptive Drugs 0.000 description 5
- 239000003539 oral contraceptive agent Substances 0.000 description 5
- 239000000583 progesterone congener Substances 0.000 description 5
- 229940053934 norethindrone Drugs 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 229960003309 dienogest Drugs 0.000 description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000001327 anti-mineralocorticoid effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002561 ketenes Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
排卵率 | 平均不规则出血率 | |
实施例一 | 2% | 2.8 |
实施例二 | 1% | 2.4 |
实施例三 | 1% | 3.6 |
实施例四 | 0 | 3.6 |
实施例五 | 4% | 3.4 |
实施例六 | 4% | 3.2 |
实施例七 | 1% | 6.6 |
实施例八 | 1% | 7.2 |
对照组一 | 95% | 1.2 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510039588.6A CN104546870B (zh) | 2015-01-27 | 2015-01-27 | 一种避孕药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510039588.6A CN104546870B (zh) | 2015-01-27 | 2015-01-27 | 一种避孕药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104546870A CN104546870A (zh) | 2015-04-29 |
CN104546870B true CN104546870B (zh) | 2018-01-12 |
Family
ID=53064646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510039588.6A Expired - Fee Related CN104546870B (zh) | 2015-01-27 | 2015-01-27 | 一种避孕药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104546870B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110548034A (zh) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | 一种怀孕阻断药物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
AU759925B2 (en) * | 1997-09-12 | 2003-05-01 | Wyeth | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
EP2432474A1 (de) * | 2009-05-22 | 2012-03-28 | Bayer Pharma Aktiengesellschaft | Arzneimittel zur oralen verabreichung, enthaltend mindestens ein estrogen und/oder mindestens ein gestagen und mindestens einen probiotischen bakterien-stamm |
-
2015
- 2015-01-27 CN CN201510039588.6A patent/CN104546870B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104546870A (zh) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101928321B1 (ko) | 프로게스틴/에스트라디올 경피 젤 | |
US8076319B2 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
KR101812160B1 (ko) | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 | |
AU2012293593B2 (en) | Use of estetrol as emergency contraceptive | |
US20100021529A1 (en) | Step-down estrogen regimen for women receiving estrogen therapy | |
DK155308B (da) | Tre-trinskombinationspraeparat til oral svangerskabsforebyggelse | |
CN101232869A (zh) | 局部给药的凝胶组合物 | |
EP2285383A2 (de) | Sequentielle verarbeitung von 20,20,21,21-pentafluor-17-hydroxy-11 -ý4-(hydroxyacetyl) phenyl¨-19-nor-17 -pregna-4,9-dien-3-on und einem oder mehreren gestagenen zur behandlung gynäkologischer erkrankungen | |
JP2014024873A (ja) | 更年期障害関連症候群の治療 | |
EP2207544A2 (en) | Treatment of oestrogen dependant conditions in pre-menopausal women | |
ES2279515T3 (es) | Antagonistas competitivos de la progesterona para el control de la fertilidad femenina, orientado a las necesidades de uso. | |
CN104546870B (zh) | 一种避孕药 | |
CN104203246A (zh) | 治疗妇科疾病的方法 | |
US20030018018A1 (en) | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea | |
EP1635843B1 (en) | Therapy comprising dienogest for hormone replacement and depression | |
Mansour | Use of the new progestogens in contraception and gynaecology | |
CA3015781C (en) | An improved formulation of long-acting levonorgestrel butanoate injectable depot suspension | |
Yuzpe et al. | Postcoital contraception | |
Spitz | Proven and potential clinical applications of mifpristone (RU486) | |
CN104540496A (zh) | 用于制备含低剂量米非司酮的速释型口服施用片剂的制剂、如此得到的片剂及其制备方法 | |
DK174181B1 (da) | Farmaceutisk præparat til hormonbehandling | |
CA3234836A1 (en) | Contraceptive regimen including reduced level of estrogen | |
CN110772476A (zh) | 一种雌二醇阴道膨胀栓及其制备方法和用途 | |
Panay et al. | PROGESTOGEN INTOLERANCE IN THE TREATMENT OF SEVERE PREMENSTRUAL SYNDROME | |
Kuttenn | Progestogen-only methods of contraception |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191204 Address after: No.1 Xiangzhang Road, Jianghua Economic Development Zone, Tuojiang Town, Jianghua Yao Autonomous County, Yongzhou City, Hunan Province Patentee after: Jianghua Yao Autonomous County Jinniu Development and Construction Co., Ltd. Address before: 273500 Shandong Jining Zoucheng Taiping Town Family Planning Service Station Patentee before: Tang Fanlan |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180112 Termination date: 20200127 |
|
CF01 | Termination of patent right due to non-payment of annual fee |